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Abstract 
Background: The concept of antibody dependent enhancement (ADE) of dengue virus (DENV) infection is a 
cornerstone of our current understanding of dengue pathogenesis, although some questions as to the mechanism 
remain, particularly in regards to the behavior of low and high passage virus isolates. This study utilized two low pas-
sage DENV 4 isolates and a laboratory adapted DENV 4 isolate to investigate the potential of low passage isolates to 
undergo ADE.
Results: Little or no ADE of infection was observed on day 2 post infection with low passage isolates, while high 
enhancement of infection was seen with the laboratory adapted virus. However, both of the low passage isolates 
showed high levels of infection (60–100 %) by day 5 post infection.
Conclusions: These results show that low passage DENV 4 viruses undergo ADE mediated infection, but that the 
process is significantly temporally delayed as compared to laboratory adapted DENV 4.
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Background
Dengue virus is the most important mosquito transmit-
ted human viral disease worldwide. Each year there are 
believed to be some 400 million cases of infection, of 
which some 100 million show some symptoms [1]. Symp-
tomatic infections result in a broad spectrum of disease, 
ranging from a mild undifferentiated fever, to dengue 
fever to more severe presentations of dengue hemor-
rhagic disease and dengue shock syndrome [2]. Fatalities 
can result from infection with dengue virus, although 
these are relatively infrequent where adequate hospitali-
zation facilities and appropriate expertise are available 
[3].
The species Dengue virus (Family Flaviviridae, Genus 
Flavivirus) comprises four distinct viruses termed Den-
gue virus (DENV) 1–4. Primary infection in a naïve 
individual results in the generation of broad and robust 
acquired immunity, offering long term, and possibly life-
long immunity to the infecting DENV, however, only 
transient immunity is generated against infections with 
heterotypic DENVs [3]. Importantly some antibodies 
raised against the initial DENV can recognize but not 
neutralize a heterotypic virus and these DENV:non-
neutralizing antibody complexes can be internalized into 
Fc receptor bearing cells such as monocytes and mac-
rophages [2] cells that are normally either not susceptible 
or only poorly susceptible to direct infection with DENV. 
This process, called antibody dependent enhancement 
(ADE) of infection was largely uncovered by the work of 
Halstead and colleagues who observed that sub-neutral-
izing levels of antibodies could trigger this process [2–5]. 
In particular it is believed that ADE expands the available 
mass of target cells as well as directly leading to infec-
tion of the main immune system regulators resulting in a 
more severe presentation, and several studies have high-
lighted the relationship between second infections with 
a heterotypic virus and disease severity [6–8]. The con-
cept of ADE underpins much of our understanding of the 
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pathogenesis of DENV infections, and plays a major role 
in shaping vaccine development where efforts focus on 
generating a uniform and equal immune response to all 
four DENVs to avoid potential problems of under vacci-
nated individuals having severe disease as a consequence 
of an acquired natural infection [9].
Recently, the concept of ADE of infection was partly 
challenged by Chaichana and colleagues who showed 
that directly isolated viruses from DENV patients showed 
little or no ADE of infection in  vitro, while laboratory 
adapted viruses underwent significant ADE of infec-
tion using serum or plasma of the same patients [10]. 
The authors concluded that the source of the virus was 
an important factor in ADE, and moreover that the ADE 
of infection seen with laboratory adapted viruses in vitro 
was a consequence of repeated passage of the virus [10]. 
We recently noted a similar phenomenon with low pas-
sage (as opposed to the unpassaged viruses of Chaichana 
and colleagues) isolates of DENV 4. Using an optimized 
protocol with a monoclonal antibody we found that con-
ditions that resulted in high ADE of infection of U937 
cells with a laboratory adapted virus resulted in little or 
no infection with low passage viruses [11]. The publi-
cation of the Chaichana paper [10] who did not look at 
DENV 4 in their study prompted the current study in 
which we conducted a more complete analysis than our 
preliminary study [11] to try to find why low passage 
DENV 4s apparently failed to undergo ADE of infection. 
Surprisingly, we show that low passage DENV 4 isolates 
do indeed undergo ADE of infection, but that this is sig-
nificantly temporally delayed as compared to laboratory 
adapted viruses.
Results and discussion
Undifferentiated U937 cells are highly susceptible to 
ADE mediated DENV infection, but are poorly suscep-
tible to direct DENV infection [12, 13]. Previous stud-
ies have suggested that low passage DENVs or DENVs 
isolated directly from patients do not undergo ADE, 
or undergo ADE only poorly in comparison to labora-
tory adapted viruses [10, 11]. To investigate this further, 
three DENV 4 isolates were selected, one of which was 
a high passage laboratory (LAB) adapted virus (DENV 4 
LAB), one a DENV 4 isolated from a dengue fever (DF) 
patient and passaged three times in C6/36 (DENV 4 
DF) and one a DENV 4 isolated from a dengue hemor-
rhagic fever (DHF) patient and passaged three times in 
C6/36 (DENV 4 DHF). Under standard conditions, these 
three viruses were incubated with either no antibody or 
increasing dilutions of an antibody produced by hybrid-
oma HB 114, which we have previously shown to be able 
to mediate ADE with DENV 4 LAB [12]. Cells were incu-
bated under standard conditions and collected on days 1, 
2, 3 and 5 post infection before analysis by flow cytom-
etry to determine the degree of infection. Results (Fig. 1) 
show high levels infection enhancement with DENV 4 
LAB from day 2 post infection, with maximum enhance-
ment observed with antibody dilutions between 1:200 
and 1:2000, consistent with our previous observations 
[12]. Significantly, both DENV 4 DF and DENV 4 DHF 
showed little or no ADE on day 2 post infection, but by 
day 3 (DENV 4 DF) or day 5 (DENV 4 DHF) post infec-
tion, cells infected with low passage isolates showed high 
degrees of infection, with maximum enhancement being 
observed with antibody dilutions of 1:200. Notably, cells 
infected with DENV 4 DF showed nearly 100 % infection 
by day 5 post infection, while cells infected with DENV 4 
DHF showed approximately 60 % infection.
These results suggest that either the low passage iso-
lates are entering the cells during the infection period 
but are undergoing significantly delayed replication, or 
that the infection process itself is delayed as compared to 
laboratory adapted viruses. The concept of delayed rep-
lication has been previously established with West Nile 
virus [14], and it is believed that virulent viruses replicate 
more slowly to evade innate immune detection, while 
attenuated viruses undergo rapid replication triggering a 
stronger innate immune response.
To address this issue, an optimized condition of ADE 
of multiplicity of infection (m.o.i.) 1 and a 1:200 dilution 
of antibody was selected and after the 2 h incubation of 
cells with the virus–antibody complex, cells were washed 
to remove un-internalized virus complexes and subse-
quently incubated in standard medium. A marked reduc-
tion in the level of DENV 4 LAB infection was seen, but 
only minimal levels (<20 %) of infection were seen with 
the two low passage isolates (Fig. 2a), even by day 5 post 
infection. When the washing step was omitted, high lev-
els of infection were again seen with DENV 4 DF by day 
3 and DENV 4 DHF by day 5 (Fig.  2b). Control experi-
ments using an isotyped matched anti-alphavirus anti-
body showed no evidence of infection above levels seen 
with no antibody (Fig. 2b). These experiments show that 
it is not virus replication that is delayed in the low pas-
sage isolates, but the infection process itself. In parallel 
with these experiments, cells were incubated with virus 
but with no antibody. These are effectively an assessment 
of the ability of the viruses to directly enter into U937 
cells in the absence of antibody–virus complex forma-
tion. Some (<20  %) direct infection was observed with 
DENV 4 LAB was observed, but no direct entry was seen 
with the low passage isolates.
To provide further confirmation of the delayed infec-
tion of U937 cells with low passage isolates, the superna-
tants from the infections with the washing step omitted, 
but antibody included (as shown in Fig. 2b) were assayed 
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for infectious virus titer on days 0 to day 5 post infection 
by standard plaque assay. Results (Fig.  2c) showed that 
the virus titer for DENV 4 LAB was over input titer (as 
assayed on “day 0”) by day 2 post infection, virus titers for 
DENV 4 DF and DENV 4 DHF were over input virus on 
days 3 and 5 respectively (Fig. 2c). These results are con-
sistent with the data for percentage of infection as deter-
mined by flow cytometry (Fig. 2b).
In a final series of experiments, the infection was again 
repeated without washing after incubation of the virus or 
virus–antibody complex with cells, and this time a 1:1000 
dilution of antibody was added daily to all infections. 
This included cells that were infected with virus that did 
not have the initial antibody-complex formation step (i.e. 
direct infection), but antibody was added daily to the 
culture medium. Results (Fig. 2d) showed high levels of 
infection in all samples. Levels of infection of DENV 4 
LAB and DENV 4 DF apparently dropped after reaching 
a peak, but this was due to increasing numbers of dead 
cells in the culture media (although this was not formally 
evaluated). Importantly, high levels of infection were also 
seen in the experiments in which no antibody had been 
added during the original infection period, but only sup-
plemented post infection (Fig. 2d).
Combined, these results clearly show that low pas-
sage DENV 4 isolates undergo ADE of infection in the 
presence of a suitable antibody, but that the process is 
somewhat temporally delayed with low passage isolates 
as compared to laboratory adapted viruses. Adding anti-
body daily after the initial infection markedly improved 
the level of infection, and suggests that the standard 
infection protocol of allowing antibody–virus complex 
to form prior to infection is not necessary. Although our 
study uses low passage DENV 4 isolates and not unpass-
saged isolates as used by Chaichana and colleagues [10], 
our results with DENV 4 DHF, in which no infection was 
seen until day 5 would be consistent with their observa-
tions which were taken to only day 3 post infection. The 
somewhat earlier infection seen with DENV 4 DF would 
support their observation that the source of the virus is 
important. Previous studies have suggested that ADE of 
infection has both an extrinsic and an intrinsic compo-
nent [15]. Extrinsic ADE is the increased uptake of virus/
antibody complexes, while intrinsic ADE is the suppres-
sion of innate immune responses [16]. In this case, it is 
possible that the low passage DENV 4 isolates do not 
suppress innate immunity as well as the high passage 
isolate, leading to the comparatively delayed infection 
profile.
Conclusions
While limited in scope, this study has shown that there 
is significant variation in the time profile of ADE infec-
tion of different DENVs. The mechanism requires further 
investigation, but the study highlights the need to look at 
longer time points when using low passage viruses.
Methods
Ethics
The two low passage DENV isolates described in this 
study were originally collected in 2006 after written 
Fig. 1 ADE of infection of U937 cells with high and low passage 
DENVs. Antibody–virus complexes were generated with a DENV 4 
LAB, b DENV 4 DF and c DENV 4 DHF and different dilutions of HB 114 
antibodies before incubation with U937 cells and subsequent culture 
for 1–5 days post infection. The degree of infection was determined 
by flow cytometry. Experiment was undertaken independently in 
triplicate and error bars show SEM
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individual informed consent in a study approved by the 
Ethical Review Committee for Research in Human Sub-
jects, Ministry of Public Health, Thailand [17, 18].
Cells and viruses
Vero (ATCC Cat No. CCL-81), LLC-MK2 (ATCC Cat No. 
CCL-7), U937 (ATCC Cat No. CRL-1593.2) and C6/36 
[19] cells were cultured exactly as described previously 
[20]. Laboratory adapted DENV 4 (strain 1036; GenBank 
accession KM519590) was propagated exactly as described 
previously [12]. The virus used had been passaged 5 times 
in mammalian cells and 4 times in C6/36 cells before use in 
this study. Two strains of DENV 4 used were isolated from 
a dengue fever patient and a dengue hemorrhagic fever 
patient DENV 4DF (GenBank accession: KM519591) and 
DENV 4DHF (GenBank accession: KM519592) respec-
tively. These viruses were passaged three times in C6/36 
cells before use in this study. Both patients were sero-
logically identified as having secondary infections. These 
viruses were passaged three times in C6/36 before being 
stored at −80  °C until required. Virus titer of all viruses 
was determined by standard plaque assay on LLC-MK2 
cells, essentially as described elsewhere [21].
ADE infection protocol and evaluation of infection
Stock DENV at a m.o.i. of 1 was incubated with either 
RPMI or with increasing dilutions of a monoclonal anti-
body purified in house from hybridoma HB114 [22] 
Fig. 2 Analysis of ADE infection of U937 cells with high and low passage DENVs. DENV 4 LAB, DENV 4 DF or DENV 4 DHF were incubated with a 
1:200 dilution of monoclonal antibody HB114 (+HB 114) or with an isotype matched anti-alphavirus antibody (+alpha) control as appropriate, 
or with an equivalent volume of medium before incubation with U937 cells for 2 h after which cells were a washed with PBS and incubated with 
normal growth media (RPMI supplemented with 10 % FBS) with daily addition of normal medium to the cells, or b incubated with normal growth 
media with daily addition of normal medium to the cells or d incubated with normal growth media with daily addition of normal growth medium 
containing a 1:1000 dilution of HB 114 antibodies. Percentage infection was determined by flow cytometry and all experiments were undertaken 
independently in triplicate. Error bars show SEM M mock infection, DH (DENV 4 DHF) DF (DENV 4 DF), DL (DENV 4 LAB). c Plaque assay of superna-
tants from (b) assayed on days “0” (immediately after infection) 1, 2, 3 and 5 post infection. Input virus titer (−2 h) is also displayed. Plaque assays 
were undertaken independently in triplicate with duplicate assay of titer
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for 1 h with constant agitation at 4  °C to generate virus 
antibody complexes which were then added to 3 ×  106 
U937 cells in RPMI medium followed by incubation at 
37 °C for a further 2 h with constant agitation. Cells were 
then resuspended to a dilution of 3 × 105 cells mL−1 in 
RPMI buffer supplemented with 10 % fetal bovine serum 
(RPMI-10  %) before incubation at 37  °C. In some cases 
cells were washed with PBS before re-suspension. Fresh 
RPMI-10  % was added daily which in some cases was 
additionally supplemented with monoclonal antibodies 
produced by hybridoma HB114 [22] at a 1:1000 dilution. 
Control experiments using an isotype matched anti-
alphavirus antibody (sc-58088; Santa Cruz Biotechnol-
ogy, Inc. Santa Cruz, CA) were additionally undertaken.
Flow cytometry to determine percentage infection 
was undertaken essentially as described elsewhere [12]. 
Briefly, approximately 1  ×  106 cells were collected by 
centrifugation at 1000×g for 5  min, blocked with 10  % 
normal goat serum (Gibco BRL, Gaithersburg, MD) in 
phosphate buffer saline (PBS) and left on ice for 30 min, 
fixed in 4  % paraformaldehyde (Sigma-Aldrich Co., St. 
Louis, MO) in PBS for 20  min and permeabilized with 
0.2  % Triton X-100 (Calbiochem, Merck KGaA, Darm-
stadt, Germany) in PBS for 10 min. After washing once 
with 1  % BSA in PBS, cells were stained for intracel-
lular expression of dengue antigen using a 1:20 dilution 
of monoclonal antibodies from hybridoma HB114 [22] 
overnight at 4 °C. Following washing twice with 1 % BSA 
in PBS a 1:40 dilution of a polyclonal goat anti-mouse 
IgG conjugated to FITC (KPL, Gaithersburg, MD) was 
used as a secondary antibody and cells were incubated 
for 1 h and then washed twice as previously. The washed 
cells were resuspended in 100 µl of PBS and analyzed by 
flow cytometry (FACS Calibur, BD Biosciences, San Jose, 
CA) using CELLQuest™ software (BD). All experiments 
were undertaken independently in triplicate. Infected 
cells were gated as M1 (Raw data is provided in Addi-
tional file 1).
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